Prognostic significance and relationship of SMAD3 phospho-isoforms and VEGFR-1 in gastric cancer: A clinicopathological study

Table 4 Association of various factors with overall survival as determined by Cox regression

Characteristics	HR (95%CI) univariate analysis	P value univariate analysis	HR (95%CI) multivariate analysis	P value multivariate analysis
Age (> 60 vs ≤ 60 yr)	1.332 (0.767-2.314)	0.309
Sex (female vs male)	0.995 (0.588-1.682)	0.985
Pathological Grade (III/IV vs I/II)	1.490 (0.885-2.511)	0.134
Clinical T stage (T3–T4 vs T1–T2)	1.974 (0.848-4.594)	0.084	1.597 (0.644-3.964)	0.312
Clinical N stage (N2–N3 vs N0-N1)	2.287 (1.299-4.026)	0.004	1.469 (0.578-3.736)	0.419
Clinical M stage (M1 vs M0)	2.664 (1.258-5.643)	0.01	1.316 (0.586-2.954)	0.506
Clinical stage (stage III–IV vs stage I-II)	2.304 (1.322-4.017)	0.003	1.210 (0.472-3.106)	0.691
Tumor size (cm) (> 5 vs ≤ 5)	2.616 (1.570-4.359)	< 0.001	2.033 (1.193-3.465)	0.009
Tumor location (antrum vs others)	0.922 (0.555-1.530)	0.753
VEGFR-1 (High vs Low)	2.360 (1.354-4.111)	0.002	1.858 (1.033-3.339)	0.038
pSMAD3C (S423/425) (high vs low)	1.069 (0.644-1.774)	0.797
TGF-β1 (high vs low)	1.399 (0.811-2.411)	0.227
pSMAD3L(S204) (high vs low)	2.884 (1.715-4.851)	< 0.001	1.943 (1.095-3.448)	0.023

HR: Hazard ratio; 95%CI: 95% confidence interval.